Texas Permanent School Fund Corp Reduces Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Texas Permanent School Fund Corp decreased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 22.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,936 shares of the medical instruments supplier’s stock after selling 3,359 shares during the quarter. Texas Permanent School Fund Corp’s holdings in West Pharmaceutical Services were worth $3,932,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Fidelis Capital Partners LLC bought a new position in West Pharmaceutical Services in the first quarter worth $27,000. Crewe Advisors LLC raised its holdings in West Pharmaceutical Services by 322.7% during the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares during the period. Quarry LP raised its holdings in West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 59 shares during the period. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services in the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services in the 1st quarter valued at $40,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

WST opened at $300.67 on Friday. West Pharmaceutical Services, Inc. has a 12-month low of $265.00 and a 12-month high of $413.70. The business’s fifty day simple moving average is $305.27 and its 200-day simple moving average is $339.16. The company has a market capitalization of $21.81 billion, a price-to-earnings ratio of 39.67, a PEG ratio of 10.61 and a beta of 1.01. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same quarter last year, the business posted $2.11 earnings per share. The company’s quarterly revenue was down 6.9% compared to the same quarter last year. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now directly owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.